Targeted Treatment of Colon Cancer with Aptamer-Guided Albumin Nanoparticles Loaded with Docetaxel

Zhen Yu,Xundou Li,Jinhong Duan,Xian-Da Yang
DOI: https://doi.org/10.2147/IJN.S267177
IF: 7.033
2020-09-11
International Journal of Nanomedicine
Abstract:Zhen Yu, Xundou Li, Jinhong Duan, Xian-Da Yang Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China Correspondence: Xian-Da Yang Email ayangmd@hotmail.com Purpose: Chemotherapy of colon cancer needs improvement to mitigate the severe adverse effects (AEs) associated with the cytotoxic drugs. The aim of this study is to develop a novel targeted drug delivery system (TDDS) with practical application potential for colon cancer treatment. Methods: The TDDS was built by loading docetaxel (DTX) in albumin nanoparticles (NPs) that were functionalized with nucleolin-targeted aptamers (AS1411). Results: The TDDS (Apt-NPs-DTX) had an average size of 62 nm and was negatively charged with a zeta potential of − 31.2 mV. DTX was released from the albumin NP with a typical sustained release profile. Aptamer-guided NPs were preferentially ingested by nucleolin-expressing CT26 colon cancer cells vs the control cells. In vitro cytotoxicity study showed that Apt-NPs-DTX significantly enhanced the killing of CT26 colon cancer cells. Importantly, compared with non-targeted drug delivery, Apt-NPs-DTX treatment significantly improved antitumor efficacy and prolonged the survival of CT26-bearing mice, without raising systemic toxicity. Conclusion: The results suggest that Apt-NPs-DTX has potential in the targeted treatment of colon cancer. Keywords: aptamer, nanoparticles, colon cancer, targeted drug delivery system
pharmacology & pharmacy,nanoscience & nanotechnology
What problem does this paper attempt to address?